Tech Company Financing Transactions
Mysthera Therapeutics Funding Round
Mysthera Therapeutics closed a $3.5 million Seed funding round on 8/21/2023. Backers included Forty51 Ventures.
Transaction Overview
Company Name
Announced On
8/21/2023
Transaction Type
Venture Equity
Amount
$3,500,000
Round
Seed
Investors
Forty51 Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its portfolio of pre-clinical stage, pan-PIM kinase inhibitors to modulate multi-lineage immune cell functions.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
St. Jakobsstrasse 17
Basel, 4052
CH
Basel, 4052
CH
Phone
Undisclosed
Website
Email Address
Overview
Mysthera was founded by Forty51 Ventures in Europe's pharma/biotech hub, Basel, in Switzerland in early 2023. The company is a preclinical stage biotech start-up focused on developing first-in-class, oral therapeutics to treat major unmet needs in autoimmune diseases. Our unique approach has potential to transform patient lives in a number of disease settings including glomerulonephritis, rheumatoid arthritis and inflammatory bowel disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Darren Cunningham
Co-Founder
Stefan Haak
Co-Founder
Marta Marti
Browse more venture capital transactions:
Prev: 8/21/2023: Moonbox venture capital transaction
Next: 8/21/2023: Prins AI venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on tech company VC transactions. All VC database entries reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs